MX2009004792A - Moduladores de la union de pai-1 para el tratamiento de trastornos oculares. - Google Patents

Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.

Info

Publication number
MX2009004792A
MX2009004792A MX2009004792A MX2009004792A MX2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A MX 2009004792 A MX2009004792 A MX 2009004792A
Authority
MX
Mexico
Prior art keywords
pai
treatment
binding
glaucoma
compound
Prior art date
Application number
MX2009004792A
Other languages
English (en)
Inventor
Iok-Hou Pang
Debra Fleenor
Abbot Clark
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2009004792A publication Critical patent/MX2009004792A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En una modalidad, la invención se refiere a un método de tratamiento del glaucoma o la PtO elevada en un paciente, que comprende administrar al paciente una cantidad efectiva de una composición que comprende un agente que modula la unión de PAI-1 a vitronectina; en otra modalidad, la invención se refiere a un método de fabricación de un compuesto para ser usado en el tratamiento del glaucoma o la PIO elevada, que comprende proveer una sustancia candidata que se sospecha que modula la unión de PAI-1, seleccionar el compuesto evaluando la capacidad de la sustancia candidata para disminuir la cantidad de PAI-1 activo en la red trabecular de un sujeto que padece glaucoma o PIO elevada, y fabricar el compuesto seleccionado.
MX2009004792A 2006-10-31 2007-10-31 Moduladores de la union de pai-1 para el tratamiento de trastornos oculares. MX2009004792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86371506P 2006-10-31 2006-10-31
PCT/US2007/083170 WO2008055205A2 (en) 2006-10-31 2007-10-31 Pai-1 binding modulators for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MX2009004792A true MX2009004792A (es) 2009-05-21

Family

ID=39345074

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004792A MX2009004792A (es) 2006-10-31 2007-10-31 Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.

Country Status (11)

Country Link
US (2) US20080107644A1 (es)
EP (1) EP2077829A2 (es)
JP (1) JP2010508306A (es)
KR (1) KR20090082401A (es)
CN (1) CN101588798A (es)
AU (1) AU2007313684A1 (es)
CA (1) CA2666316A1 (es)
MX (1) MX2009004792A (es)
RU (1) RU2465898C2 (es)
WO (1) WO2008055205A2 (es)
ZA (1) ZA200902453B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
US20090202524A1 (en) 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US9448234B2 (en) 2011-11-15 2016-09-20 National University Corporation Hamamatsu University School Of Medicine Therapeutic agent for preterm delivery or abortion using plasminogen activator inhibitor-1
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137260T3 (es) * 1992-05-22 1999-12-16 Senju Pharma Co Composicion farmaceutica para uso en el tratamiento del glaucoma.
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
EA004050B1 (ru) * 1998-12-11 2003-12-25 Бакулиш Мафатлал Хамар Способ изготовления состава местных бета-блокаторов улучшенного действия
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP1485709A4 (en) * 2002-02-19 2005-09-21 Univ Vanderbilt THERAPIES OF PAI-1 INHIBITORS AND NON-HUMAN TRANSGENIC ANIMALS FOR THE SYSTEMATIC RESEARCH OF PAI-1 INHIBITING CANDIDATES
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ctgf)의활성 및/또는 발현 조절, 저해, 또는 변조제

Also Published As

Publication number Publication date
WO2008055205A3 (en) 2008-07-17
ZA200902453B (en) 2010-07-28
RU2009120545A (ru) 2010-12-10
US20100260784A1 (en) 2010-10-14
WO2008055205A2 (en) 2008-05-08
EP2077829A2 (en) 2009-07-15
JP2010508306A (ja) 2010-03-18
CA2666316A1 (en) 2008-05-08
AU2007313684A1 (en) 2008-05-08
US20080107644A1 (en) 2008-05-08
RU2465898C2 (ru) 2012-11-10
CN101588798A (zh) 2009-11-25
KR20090082401A (ko) 2009-07-30

Similar Documents

Publication Publication Date Title
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
EA200970447A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
TW200612926A (en) Compounds and compositions as ppar modulators
TW200602330A (en) Compounds and compositions as PPAR modulators
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
NZ580963A (en) Compositions and methods for prophylaxis and treatment of addictions
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
MX2009001062A (es) Agonistas de ep2.
MX2009004792A (es) Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal